Unichem Lab Peer Comparison

NSE: UNICHEMLAB | BSE: 506690

₹472.95

₹-14.80 (-3.03%)

As on 23-Oct-2026IST

Market cap

₹3,323 Cr

Revenue (TTM)

₹2,308 Cr

P/E Ratio

10.9

P/B Ratio

1.2

Div. Yield

0 %

Edit

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	3,323	33,547	24,280	15,313	12,856
Revenue (₹ Cr)	2,308	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	304.78	1,018.97	497.77	603.02	270.18
Net Margin (%)	12.81	10.47	20.72	22.63	23.29
RoE (%)	4.96	21.30	28.49	19.61	14.45
Price to Earnings	10.90	33.17	48.78	25.39	46.68
Price-To-Book	1.21	6.41	12.01	4.39	6.20

Income Statement (₹ Cr)

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	2,307.87	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	2,379.72	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	2,079.29	7,739.53	1,608.91	1,753.71	720.01
EBITDA	228.58	1,943.92	762.90	836.69	388.38
Depreciation	123.27	425.10	98.11	78.88	74.78
EBIT	105.31	1,518.82	664.79	757.81	313.60
Interest	31.67	148.45	26.33	5.43	0.26
Other Income	71.85	47.39	30.80	73.83	51.50
Exceptional Items	204.90	-27.85	0.00	-25.66	-3.28
Profit before Tax	350.39	1,389.91	669.26	800.55	361.56
Provision for Tax	45.61	370.94	171.48	197.53	91.39
Profit after Tax	304.78	1,018.97	497.77	603.02	270.18

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	2,717.44	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	134.06	723.57	345.47	142.73	50.51
Current Liabilities	885.94	3,912.24	710.20	508.04	169.08
Total Liabilities	3,706.88	9,514.48	2,930.14	4,157.10	2,231.79

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	1,275.61	3,392.16	1,290.62	1,321.38	957.22
Current Assets	2,197.34	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	3,706.88	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	468.78	1,204.08	196.61	0.00	0.00
Net Current Assets	1,311.40	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	125.64	258.92	13.18	4.82	3.76

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	3.64	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	192.06	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	1.86	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	197.56	93.92	-56.08	-69.08	11.28

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	10.68	25.25	27.50	24.61	18.04
ROE (%)	4.96	21.30	28.49	19.61	14.45
ROA (%)	8.34	11.42	19.48	16.31	12.66
EBIT Margin (%)	4.56	15.68	28.03	29.25	28.29
Net Margin (%)	12.81	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	7.13	18.36	78.33	7.93	-6.72
EBIT Growth (%)	-14.33	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	143.86	32.39	182.61	21.66	-24.38
EPS Growth (%)	2.27	36.68	277.72	25.42	-21.99
Book Value Growth (%)	10.88	11.36	22.95	18.43	11.27

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	26.00	32.49	48.78	24.59	46.28
Price / Book Value	1.21	6.41	12.01	4.39	6.20
Dividend Yield (%)	0.00	0.20	0.18	0.40	0.61
EV/EBITDA	15.30	17.80	31.62	17.37	32.03
Market Cap (₹ Cr)	2,067.98	30,257.56	15,412.11	11,956.86	10,627.92

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.01	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.15	0.16	--	--	--
Current Ratio	2.48	1.43	2.09	5.21	7.39
Quick Ratio	1.38	0.82	1.37	3.85	5.46
Interest Coverage	12.06	10.36	26.41	148.49	1,386.30

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	35.90	26.46	22.82	41.42	41.52
Asset Turnover	0.63	1.09	0.93	0.70	0.52
Receivable days	133.23	88.68	77.32	144.58	169.86
Inventory Days	162.76	84.11	80.83	96.67	97.92
Payable days	145.35	176.65	125.94	135.45	159.68
Cash Conversion Cycle	150.64	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.